Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO

Next Previous
Trial Profile

Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Rituximab (Primary) ; Methotrexate; Methylprednisolone
  • Indications Graves ophthalmopathy
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 May 2018.
    • 09 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top